--- title: Insights | Eduard Ayuso description: Dr. Eduard Ayuso is an expert in the field of gene therapy using viral vector platforms. With more than 50 scientific publications and more than two decades of academic and industry consulting experience, Eduard has made significant contributions to the field of in vivo gene transfer in small and large animal models of diseases, as well as viral vector development and analytics. He has served as Head of Innovative Vectorology at the French National Institute of Health and Medical Research (INSERM), and as the Scientific Director of the Translational Vector Core unit at University of Nantes. Eduard earned his PhD in Biochemistry and Molecular Biology and his DVM from the Autonomous University of Barcelona. --- This is a search field with an auto-suggest feature attached. - There are no suggestions because the search field is empty. - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) [Company](https://www.siegfried.ch/company/) Company [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) Offering [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) Sustainability [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights) [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) What are you looking for? [![](https://content.siegfried.ch/hubfs/siegfried-logo.svg)](https://www.siegfried.ch/) [Company](https://www.siegfried.ch/company/) [Purpose](https://www.siegfried.ch/company/purpose/) [Strategy](https://www.siegfried.ch/company/strategy/) [Leadership](https://www.siegfried.ch/company/leadership/) [History](https://www.siegfried.ch/company/history/) [Locations](https://www.siegfried.ch/company/locations/) [Offering](https://www.siegfried.ch/offering/) [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) [Exclusive synthesis](https://www.siegfried.ch/offering/drug-substances/exclusive-synthesis/) [API portfolio](https://www.siegfried.ch/offering/drug-substances/api/) [Reference standards](https://www.siegfried.ch/reference-standards/) [Preclinical and early-phase development](https://content.siegfried.ch/siegfried-acceleration-hub) [Alkaloid raw materials extraction](https://extractas.com.au/) [Drug Products](https://www.siegfried.ch/offering/drug-products/) [Oral solid dosage forms](https://www.siegfried.ch/offering/drug-products/oral-solids/) [Sterile injectables](https://www.siegfried.ch/offering/drug-products/sterile-injectables/) [Ophthalmics](https://www.siegfried.ch/offering/drug-products/ophthalmics/) [Inhalation products](https://www.siegfried.ch/offering/drug-products/inhalatives/) [Viral vectors](https://dinamiqs.com/) [Technologies](https://www.siegfried.ch/technologies/) [Sustainability](https://www.siegfried.ch/sustainability/) [People](https://www.siegfried.ch/sustainability/people/) [Environment](https://www.siegfried.ch/sustainability/environment/environment/) [Integrity](https://www.siegfried.ch/sustainability/integrity/) [Quality](https://www.siegfried.ch/sustainability/quality/) [Community engagement](https://siegfried.ch/sustainability/community-engagement/) [Risk management](https://www.siegfried.ch/sustainability/risk-management/) [Insights](https://content.siegfried.ch/insights) - [Careers](https://www.siegfried.ch/careers/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Contact us](https://www.siegfried.ch/contact/) # Insights ## See our event recap Filter by tags [Technology](https://content.siegfried.ch/insights/tag/technology) [Early-phase development](https://content.siegfried.ch/insights/tag/early-phase-development) [Sustainability](https://content.siegfried.ch/insights/tag/sustainability) [Drug Products](https://content.siegfried.ch/insights/tag/drug-products) [Regulatory support](https://content.siegfried.ch/insights/tag/regulatory-support) [Technology](https://content.siegfried.ch/insights/tag/technology) [Early-phase development](https://content.siegfried.ch/insights/tag/early-phase-development) [Sustainability](https://content.siegfried.ch/insights/tag/sustainability) [Drug Products](https://content.siegfried.ch/insights/tag/drug-products) [Regulatory support](https://content.siegfried.ch/insights/tag/regulatory-support) [Oral solid dosage form](https://content.siegfried.ch/insights/tag/oral-solid-dosage-form) [Scale-up](https://content.siegfried.ch/insights/tag/scale-up) [Dosage Form](https://content.siegfried.ch/insights/tag/dosage-form) [Fill-finish](https://content.siegfried.ch/insights/tag/fill-finish) [Pharmaceutical Manufacturing](https://content.siegfried.ch/insights/tag/pharmaceutical-manufacturing) [Pre-filled syringes](https://content.siegfried.ch/insights/tag/pre-filled-syringes) NEW 11/7/2023 [Technology](https://content.siegfried.ch/insights/tag/technology) ### Tackling the key challenges in viral vector manufacturing [Read article](https://content.siegfried.ch/insights/tackling-the-key-challenges-in-viral-vector-manufacturing) Recent #### [Sep 28, 2026 Drug Products Oral solid dosage form Accelerating early-stage CMC development for oral drug products](https://content.siegfried.ch/insights/accelerating-early-stage-cmc-development-for-oral-drug-products-1) #### [Aug 19, 2026 Early-phase development Regulatory support More than compliance: Managing the challenges of controlled substance manufacturing](https://content.siegfried.ch/insights/more-than-compliance-managing-the-challenges-of-controlled-substance-manufacturing) #### [Jul 23, 2026 Scale-up Drug Products Dosage form scale-up: Balancing speed and efficiency in later-stage development](https://content.siegfried.ch/insights/dosage-form-scale-up-balancing-speed-and-efficiency-in-later-stage-development) #### Subscribe for more expert insights   All posts ### [Nov 7, 2023 Technology Tackling the key challenges in viral vector manufacturing](https://content.siegfried.ch/insights/tackling-the-key-challenges-in-viral-vector-manufacturing) Oct 30, 2025 ### Video: Insights from Chief Scientific Officer Stefan Randl at CPHI Frankfurt 2025 Sign up to stay up to date on Siegfried and our business performance. expect more **Siegfried AG** Untere Brühlstrasse 4 4800 Zofingen, Switzerland [+41 62 746 11 11](tel:+41627461111) [Get in touch](https://www.siegfried.ch/contact-us/) #### About us - [Our company](https://www.siegfried.ch/company/) - [Sustainability](https://www.siegfried.ch/sustainability/) - [Media](https://www.siegfried.ch/media/) - [Investors](https://www.siegfried.ch/investors/) - [Careers](https://www.siegfried.ch/careers/) #### Helpful resources - [Expert insights](https://content.siegfried.ch/insights) - [News archive](https://www.siegfried.ch/news-archive/) - [Reports](https://www.siegfried.ch/investors/investors-download-center-2025/) - [Terms and conditions](https://www.siegfried.ch/terms-and-conditions/) #### Offering - [Drug Substances](https://www.siegfried.ch/offering/drug-substances/) - [Drug Products](https://www.siegfried.ch/offering/drug-products/) - [Technologies](https://www.siegfried.ch/technologies/) 2026 © Siegfried Holding AG - [Privacy Policy](https://www.siegfried.ch/privacy-policy/) - [Legal disclaimer](https://www.siegfried.ch/legal-disclaimer/) - [Imprint](https://www.siegfried.ch/imprint/) ```json { "@context" : "https://schema.org", "@type" : "VideoObject", "contentUrl" : "https://143616667.fs1.hubspotusercontent-eu1.net/hubfs/143616667/Peter%20-%20Video%2001%20Final%20v2.mp4", "dateModified" : "2025-10-31T17:20:09.538Z", "duration" : "PT2M16S", "height" : 1080, "name" : "Peter - Video 01 Final v2", "thumbnailUrl" : "https://143616667.fs1.hubspotusercontent-eu1.net/hubfs/143616667/Peter%20-%20Video%2001%20Final%20v2.mp4/medium.jpg", "uploadDate" : "2025-10-28T21:59:19.239Z", "width" : 1920 } ```